A Phase II Study of LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Latest Information Update: 18 Apr 2024
At a glance
- Drugs LMB 100 (Primary) ; Pembrolizumab
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- 29 Feb 2024 Status changed from active, no longer recruiting to discontinued, this study was terminated due to slow accrual.
- 01 Sep 2022 Status changed from recruiting to active, no longer recruiting.
- 15 May 2021 Planned End Date changed from 31 Mar 2022 to 31 Mar 2024.